Biocryst Pharmaceuticals (BCRX) Free Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -3.13% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 16.01% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -1.95% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -20.15% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 21.16% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 80.69% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -0.65% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.29 Bn | 1.94 Bn | 214.41 Mn | 94.97% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 94.97% |
| Mar 31, 2026 | -9.39% |
| Dec 31, 2025 | 140.70% |
| Sep 30, 2025 | 47.89% |
| Jun 30, 2025 | 51.37% |
| Mar 31, 2025 | 29.28% |
| Dec 31, 2024 | 44.02% |
| Sep 30, 2024 | 32.88% |
| Jun 30, 2024 | 61.27% |
| Mar 31, 2024 | 4.09% |
| Dec 31, 2023 | 39.46% |
| Sep 30, 2023 | 18.39% |
| Jun 30, 2023 | 14.74% |
| Mar 31, 2023 | -26.78% |
| Dec 31, 2022 | -32.29% |
| Sep 30, 2022 | -5.57% |
| Jun 30, 2022 | -4.43% |
| Mar 31, 2022 | -42.39% |
| Dec 31, 2021 | -11.69% |
| Sep 30, 2021 | 12.32% |